Effects of calcium channel blocker, nifedipine, on antidepressant activity of fluvoxamine, venlafaxine and tianeptine in mice
Keywords:Antidepressant, Fluvoxamine, Nifedipine, Tianeptine, Venlafaxine
Background: Cardiovascular diseases are commonly associated with depression. Calcium channel blockers (CCBs) form commonly used group of drugs for the treatment of a number of cardiovascular diseases. Nifedipine, a CCB, has been shown to possess antidepressant activity and potentiate antidepressant activity of imipramine and sertraline, however, literature on its interaction with newer antidepressant drugs such as fluvoxamine, venlafaxine and tianeptine is limited. Hence, the present study was undertaken.
Methods: The study was carried out in albino mice in two phases. In Phase I, antidepressant activity of nifedipine, fluvoxamine, venlafaxine and tianeptine were confirmed after their single dose administration using forced swim test (FST) and tail suspension test (TST) and their minimum antidepressant doses were determined. In Phase II, the effect of nifedipine on antidepressant activity of fluvoxamine, venlafaxine and tianeptine was studied by orally administering sub-antidepressant doses of these drugs for 28 days. FST and TST were carried out on 1st, 14th and 28th day of the study and change in immobility period was observed.
Results: In Phase I, all the studied drugs exhibited dose dependent antidepressant activity in both FST and TST. Minimal antidepressant dose of nifedipine, fluvoxamine, venlafaxine and tianeptine was observed as 10, 25, 25 and 10 mg/kg respectively. In Phase II, combinations of sub-antidepressant dose of nifedipine (5 mg/kg) with sub-antidepressant doses of fluvoxamine (12.5 mg/kg), venlafaxine (12.5 mg/kg) and tianeptine (5 mg/kg) exhibited enhanced antidepressant activity when compared to the control group and individual drug groups after same duration of treatment.
Conclusions: Nifedipine, fluvoxamine, venlafaxine and tianeptine possess antidepressant activity and nifedipine exhibits synergistic antidepressant activity with fluvoxamine, venlafaxine and tianeptine.
Perlis RH, Ostacher MJ, Uher R, Nierenberg AA, Casamassima F, Kansky C, et al. Stability of symptoms across major depressive episodes in bipolar disorder. Bipolar Disord. 2009;11(8):867-75.
Nemeroff CB, Musselman DL, Evans DL. Depression and cardiac disease. Depress Anxiety. 1998;8 Suppl 1:71-9.
Smith AB, Cunnane TC. Multiple calcium channels control neurotransmitter release from rat postganglionic sympathetic nerve terminals. J Physiol. 1997;499 (Pt 2):341-9.
Aburawi S, Al-Tubuly R, Alghzewi E, Gorash Z. Effects of calcium channel blockers on antidepressant action of Alprazolam and Imipramine. Libyan J Med. 2007;2(4):169-75.
Oriaifo SE, Omogbai EKI. Nifedipine enhances the antidepressant response of sertraline and imipramine. Int Res J Pharm Pharmacol. 2013;3(4):46-52.
Committee for the Purpose of Control and Supervision on Experiments on Animals. CPCSEA guidelines for laboratory animal facility. Indian J Pharmacol. 2003;35:257-74.
Chenu F, Guiard BP, Bourin M, Gardier AM. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behav Brain Res. 2006;172(2):256-63.
Psychotropic and neurotropic activity: antidepressant activity. In: Vogel HG, editor. Drug Discovery and Evaluation: Pharmacological Assays. 3rd Edition. Berlin, New York: Springer-Verlag, Heidelberg; 2008: 774-815.
Duman CH. Models of depression. Vitam Horm. 2010;82:1-21.
Dedic N, Walser SM, Deussing JM. Mouse models of depression. In: Psychiatric Disorders – Trends and Developments. InTech; 2011: 185-222. Available at http://www.intechopen.com/download/pdf/22663. Accessed 12 Mar 2014.
Bandyopadhyay D. Study on exploration of effect of voltage gated calcium channel blockers on the anti-depressant action of imipramine and alprazolam. J Drug Deliv Ther. 2013;3(2):239-42.
Ushijima K, Sakaguchi H, Sato Y, To H, Koyanagi S, Higuchi S, et al. Chronopharmacological study of antidepressants in forced swimming test of mice. J Pharmacol Exp Ther. 2005;315(2):764-70.
Ide S, Fujiwara S, Fujiwara M, Sora I, Ikeda K, Minami M, et al. Antidepressant-like effect of venlafaxine is abolished in µ-opioid receptor-knockout mice. J Pharmacol Sci. 2010;114(1):107-10.
Solich J, Palach P, Budziszewska B, Dziedzicka-Wasylewska M. Effect of two behavioral tests on corticosterone level in plasma of mice lacking the noradrenaline transporter. Pharmacol Rep. 2008;60(6):1008-13.
Szkutnik-Fiedler D, Kus K, Balcerkiewicz M, Grzeskowiak E, Nowakowska E, Burda K, et al. Concomitant use of tramadol and venlafaxine - evaluation of antidepressant-like activity and other behavioral effects in rats. Pharmacol Rep. 2012;64(6):1350-8.
O’Donnel JM, Shelton RC. Drug therapy of depression & anxiety disorders. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th Edition. New York: McGraw Hill; 2011: 397-415.
De Batista C. Antidepressants agents. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic & Clinical Pharmacology. 12th Edition. New York: The McGraw Hill; 2012: 521-37.
Berger M, Roth B. Pharmacology of serotonergic and central adrenergic neurotransmission. In: Golan DE, Tashijan AH, Armstrong EJ, Armstrong AW, editors. Principles of Pharmacology- The Pathophysiologic Basis of Drug Therapy. 3rd Edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2012: 207-24.
Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat CNS Drug Discov. 2006;1(1):29-41.
De Simoni MG, De Luigi A, Clavenna A, Manfridi A. In vivo studies on the enhancement of serotonin reuptake by tianeptine. Brain Res. 1992;574(1-2):93-7.
Kim YJ, Shin MC, Kim SA, Chung JH, Kim EH, Kim CJ. Modulation of tianeptine on ion currents induced by inhibitory neurotransmitters in acutely dissociated dorsal raphe neurons of Sprague-Dawley rats. Eur Neuropsychopharmacol. 2002;12(5):417-25.
Marinesco S, Poncet L, Debilly G, Jouvet M, Cespuglio R. Effects of tianeptine, sertraline and clomipramine on brain serotonin metabolism: a voltammetric approach in the rat. Brain Res. 1996;736(1-2):82-90.
Invernizzi R, Pozzi L, Garattini S, Samanin R. Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism. Neuropharmacology. 1992;31(3):221-7.
Dziedzicka-Wasylewska M, Rogoz Z, Skuza G, Dlaboga D, Maj J. Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2)/D(3) receptors. Behav Pharmacol. 2002;13(2):127-38.
Bolaños-Jiménez F, Manhães de Castro R, Fillion G. Effect of chronic antidepressant treatment on 5-HT1B presynaptic heteroreceptors inhibiting acetylcholine release. Neuropharmacology. 1994;33(1):77-81.
Wegener G, Volke V, Harvey BH, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res. 2003;959(1):128-34.
Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord. 2001;63(1-3):221-4.
Harkin AJ, Bruce KH, Craft B, Paul IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol. 1999;372(3):207-13.
Helmeste DM, Tang SW. The role of calcium in the etiology of the affective disorders. Jpn J Pharmacol. 1998;77(2):107-16.
Reiser G, Donié F, Binmöller FJ. Serotonin regulates cytosolic Ca2 activity and membrane potential in a neuronal and in a glial cell line via 5-HT3 and 5-HT2 receptors by different mechanisms. J Cell Sci. 1989;93:545-55.
Das P, Bell-Horner CL, Huang RQ, Raut A, Gonzales EB, Chen ZL, et al. Inhibition of type A GABA receptors by L-type calcium channel blockers. Neuroscience. 2004;124(1):195-206.